On surface level, investors practically have every reason to doubt pet medications and supplies specialist PetMed Express (PETS). Though tied to a fundamentally relevant industry, PETS stock failed to demonstrate in recent years its viability for stakeholders. For example, since the January opener, PETS stumbled nearly 14%. In the past 365 days, it’s down almost 30%.
Drill a little deeper and once again, PetMed appears an incredibly risky and vulnerable enterprise. Earlier this year, the company released its earnings report for the quarter ended December 2022, which failed to meet expectations. Worryingly, top-line sales have been fading since fiscal year 2021, practically pushing investors to the exits.
